As I was waiting to get my second Lu-177 dose yesterday, I asked one of the Dana Farber people involved with my trial what he knew about the Novartis delay in production. He said an FDA report had just been released, and I found the following with a quick search:
fiercepharma.com/pharma/nov...
Excerpts:
"One month on, Novartis’ surprise radiotherapy production halt could be nearing its end, the company said Wednesday. Meanwhile, an FDA write-up has shed more light on the manufacturing hitches that likely played a role in the temporary supply squeeze on Novartis’ cancer meds Lutathera and Pluvicto."
"Quality issues, record-keeping shortfalls and cleaning deficits are just a few of the problems the FDA flagged at Novartis’ Millburn, New Jersey, plant during an inspection last fall. It remains unclear whether the production halt is directly tied to the FDA’s November inspection..."
"A company spokesperson said over email Wednesday that the company is 'preparing to restart radioligand therapy production' at the two affected sites and currently expects patients to start receiving doses again in a phased manner starting early this month.
“ 'As radiopharmaceutical therapies are made to order for specific patients and require coordination of radioisotope components, there is a need to plan ahead in order to ensure on-time delivery,' the spokesperson continued. 'As a result, Novartis has contacted treatment sites to reopen the ordering process as it prepares to restart production, so that it can more quickly and efficiently supply doses to patients. We expect that initial production supply may be limited as the different sites and lines restart, but we will do everything possible to address the accumulation of patient demand from these past few weeks as quickly as we can,' the spokesperson added."
Novartis still sees “no indication of any risk to patients from doses previously produced at these sites."